Advertisement
Dr. Eagling brings to J-Pac and Doyen Medipharm 30 years of industryexperience in the medical device, diagnostic, life science andbiopharmaceutical fields. Dr. Eagling has been responsible for leading largedivisions of several companies including Ciba Corning Diagnostics, OridionMedical, Integrated Biosystems and most recently Stedim Biosystems.Additionally, Dr. Eagling previously served as the President and CEO of GameraBioscience.
Advertisement
"We believe Richard's experience and proven success with global companies,working in organizations both larger and smaller than J-Pac, will help uscontinue to capitalize on the tremendous opportunities for growth ahead of us.We are sure that his commitment, integrity, and interpersonal style will fitextremely well with the culture and values of our entire team," said BrianGuthrie, a General Partner at Riverside Partners and Chairman of the Board ofJ-Pac.
"I am extremely excited to build upon the great medical manufacturingplatform that Bill McLaughlin and his team has created at J-Pac and DoyenMedipharm and am looking forward to leading the Company's next phase ofgrowth. We will continue to focus on providing high quality advanced drugdelivery and related medical products to the world's leading OEMs," said Dr.Eagling.
About J-Pac and Doyen Manufacturing
Headquartered in Somersworth, NH, J-Pac is a leading contract manufacturerand equipment maker for medical device and biopharmaceutical OEMs. J-Pac'scontract manufacturing division specializes in medical devices, medicalpackaging and trays, and advanced medical device and drug delivery systems.Through its Doyen Division, J-Pac also provides precision high-volumeproduction equipment to medical device and biopharmaceutical OEMs around theworld.
About Riverside Partners
Founded in 1989, Riverside Partners is a middle market private equity firmcurrently investing Riverside Fund III, L.P. The fund focuses ongrowth-oriented companies in the healthcare and technology industries.Riverside is particularly experienced at partnering with founders, owners andmanagement teams and it brings substantial domain expertise and operatingexperience to its portfolio companies. The partners at Riverside have managedmore than $500 million in investments in over 50 companies. We are currentlyfocused on companies with revenues between $20 - $200 million and with $5 -$25 million of EBITDA.
SOURCE Riverside Partners
